Mobile |
Deutsch |
Español |
Français |
日本語 |
한국어 |
Português |
Русский |
中文 |
العربية |
PATENTSCOPE
Search International and National Patent Collections
Options
Query
Result
Interface
Office
Translate
Query Language
All
Arabic
Bulgarian
Chinese
Danish
English
Estonian
French
German
Hebrew
Indonesian
Italian
Japanese
Korean
Laotian
Polish
Portuguese
Romanian
Russian
Spanish
Swedish
Thai
Vietnamese
Stem
Sort by:
Relevance
Pub Date Desc
Pub Date Asc
App Date Desc
App Date Asc
List Length
10
50
100
200
Result List Language
Query Language
English
Spanish
Korean
Vietnamese
Hebrew
Portuguese
French
German
Japanese
Russian
Chinese
Italian
Polish
Danish
Swedish
Arabic
Estonian
Indonesian
Thai
Bulgarian
Laotian
Romanian
Displayed Fields
Application Number
Publication Date
Abstract
Applicant Name
Int. Class
Image
Inventor Name
Chart/Graph
Table
Graph
Group by
*
None
Offices of NPEs
IPC code
Applicants
Inventors
Filing Dates
Publication Dates
Countries
No of Items/Group
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Download Fields
NPEs
Default Search Form
Simple
Advanced Search
Field Combination
Browse by Week (PCT)
Cross Lingual Expansion
Translator
Simple
Advanced Search
Field Combination
Browse by Week (PCT)
Cross Lingual Expansion
Translator
Default Tab Search Form
Front Page
Any Field
Full Text
ID/Numbers
IPC
Names
Dates
Front Page
Any Field
Full Text
ID/Numbers
IPC
Names
Dates
Interface Language
English
Deutsch
Français
Español
日本語
中文
한국어
Português
Русский
English
Deutsch
Français
Español
日本語
中文
한국어
Português
Русский
Multiple Windows Interface
Tooltip Help
IPC Tooltip Help
Instant Help
Expanded Query
Office:
All
All
PCT
Africa
African Regional Intellectual Property Organization (ARIPO)
Egypt
Kenya
Morocco
Tunisia
South Africa
Americas
United States of America
Canada
LATIPAT
Argentina
Brazil
Chile
Colombia
Costa Rica
Cuba
Dominican Rep.
Ecuador
El Salvador
Guatemala
Honduras
Mexico
Nicaragua
Panama
Peru
Uruguay
Asia-Europe
Australia
Bahrain
China
Denmark
Estonia
Eurasian Patent Office
European Patent Office (EPO)
France
Germany
Germany(DDR data)
Israel
Japan
Jordan
Portugal
Russian Federation
Russian Federation(USSR data)
Saudi Arabia
United Arab Emirates
Spain
Republic of Korea
India
United Kingdom
Georgia
Bulgaria
Italy
Romania
Lao People's Democratic Republic
Asean
Singapore
Viet Nam
Indonesia
Cambodia
Malaysia
Brunei Darussalam
Philippines
Thailand
WIPO translate (Wipo internal translation tool)
Search
Simple
Advanced Search
Field Combination
Cross Lingual Expansion
Chemical compounds (login required)
Browse
Browse by Week (PCT)
Gazette Archive
National Phase Entries
Full download
Incremental download (last 7 days)
Sequence listing
IPC Green Inventory
Portal to patent registers
Translate
WIPO Translate
WIPO Pearl
News
PATENTSCOPE News
Login
ui-button
Login
Account Sign Up
Options
Options
Help
ui-button
How to Search
User Guide PATENTSCOPE
User Guide: Cross Lingual Expansion
User Guide: ChemSearch
Query Syntax
Fields Definition
Country Code
Data Coverage
PCT applications
PCT national phase entry
National collections
Global Dossier public
FAQ
Feedback&Contact
INID codes
Kind codes
Tutorials
About
Overview
Terms And Conditions
Disclaimer
Home
IP Services
PATENTSCOPE
Machine translation
Wipo Translate
Arabic
German
English
Spanish
French
Japanese
Korean
Portuguese
Russian
Chinese
Google Translate
Bing/Microsoft Translate
Baidu Translate
Arabic
English
French
German
Spanish
Portuguese
Russian
Korean
Japanese
Chinese
...
Italian
Thai
Cantonese
Classical Chinese
Some content of this application is unavailable at the moment.
If this situation persist, please contact us at
Feedback&Contact
1. (WO2013106646) COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE
PCT Biblio. Data
Description
Claims
National Phase
Notices
Documents
Latest bibliographic data on file with the International Bureau
PermaLink
PermaLink
Bookmark
Pub. No.:
WO/2013/106646
International Application No.:
PCT/US2013/021141
Publication Date:
18.07.2013
International Filing Date:
11.01.2013
IPC:
C07D 413/12
(2006.01) ,
C07D 417/12
(2006.01) ,
A61K 31/42
(2006.01) ,
A61K 31/427
(2006.01) ,
A61P 35/00
(2006.01)
C
CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
413
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C
CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
A
HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
42
Oxazoles
A
HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
427
not condensed and containing further heterocyclic rings
A
HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
YALE UNIVERSITY
[US/US]; Two Whitney Avenue New Haven, CT 06511, US
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
[GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS, GB
CAMBRIDGE ENTERPRISE LIMITED UNIVERSITY OF CAMBRIDGE
[GB/GB]; Hauser Forum 3 Charles Babbage Road Cambridge CB3 0GT, GB
Inventors:
CREWS, Craig, M.
; US
BUCKLEY, Dennis
; US
CIULLI, Alessio
; GB
JORGENSEN, William
; US
GAREISS, Peter, C.
; US
MOLLE, Inge, Van
; GB
GUSTAFSON, Jeffrey
; US
TAE, Hyun-Seop
; US
MICHEL, Julien
; GB
HOYER, Dentin, Wade
; US
ROTH, Anke, G.
; DE
HARLING, John, David
; GB
SMITH, Ian Edward, David
; GB
MIAH, Afjal, Hussain
; GB
CAMPOS, Sebastian, Andre
; GB
LE, Joelle
; GB
Agent:
COLEMAN, Henry, D.
; Coleman Sudol Sapone, P.C. 714 Colorado Avenue Bridgeport, CT 06605-1601, US
Priority Data:
61/585,736
12.01.2012
US
Title
(EN)
COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE
(FR)
COMPOSÉS ET PROCÉDÉS POUR L'INHIBITION DE L'UBIQUITINE LIGASE VCB E3
Abstract:
(EN)
The present invention relates to novel compounds which find utility as modulators, especially inhibitors of VCB E3 Ubiquitin Ligase and as bioactive agents for use as therapeutics for the stimulation of erythropoiesis in a patient or subject including inducement of EPO production in the patient or subject, for the treatment of chronic anemia and ischemia (limits brain injury during episodes of localized anemia, ischemia and/or stroke and damage to cardiovascular tissue during cardiovascular ischemia), as well as enhancing wound healing processes. Pharmaceutical compositions comprising effective amounts of compounds according to the present invention alone or in combination with an additional erythropoieses stimulating agent such as EPO under the tradename procrit or epogen or darbapoietin alfa under the tradename aranesp. Methods of stimulating erythropoiesis in a subject or patient, including increasing the number of red blood cells and/or hematocrit of the patient, treating anemia, including chronic anemia and anemia associated with chronic kidney disease, dialysis, and cancer chemotherapy, ischemia, stroke and damage to cardiovascular tissue during cardiovascular ischemia as well as enhancing wound healing processes and preventing/reducing scarring secondary to healing represent additional aspects of the present invention. Local enhancement of angiogenesis through induction of VEGF including wound healing and reduction of stent occlusion remain additional aspects of the present invention.
(FR)
La présente invention concerne de nouveaux composés qui trouvent une utilité comme modulateurs, en particulier inhibiteurs de l'ubiquitine ligase VCB E3 et comme agents bioactifs en vue de l'utilisation comme produits thérapeutiques pour la stimulation de l'érythropoïèse chez un patient ou un sujet, comprenant l'induction de production d'EPO chez le patient ou le sujet, pour le traitement d'anémie et d'ischémie chroniques (limite une lésion cérébrale pendant des épisodes d'anémie, ischémie et/ou accident vasculaire cérébral localisés et un endommagement au tissu cardiovasculaire pendant une ischémie cardiovasculaire), ainsi que l'amélioration des processus de cicatrisation des plaies. L'invention concerne également des compositions pharmaceutiques comprenant des quantités efficaces de composés selon la présente invention individuellement ou en combinaison avec un agent supplémentaire stimulant l'érythropoïèse, tel que l'EPO, sous la marque Procrit ou Epogène, ou la darbapoïétine alpha sous la marque Aranesp. L'invention concerne aussi des procédés de stimulation de l'érythropoïèse chez un sujet ou patient, comprenant l'augmentation du nombre de globules rouges et/ou de l'hématocrite du patient, le traitement d'anémie, comprenant l'anémie chronique et l'anémie associée à une maladie rénale chronique, la dialyse et la chimiothérapie du cancer, l'ischémie, l'accident vasculaire cérébral et un endommagement au tissu cardiovasculaire pendant une ischémie cardiovasculaire ainsi que l'amélioration des processus de cicatrisation de plaies et la prévention/réduction de cicatrices consécutives à la cicatrisation. La présente invention concerne également l'amélioration locale de l'angiogenèse par l'induction de VEGF comprenant la cicatrisation des plaies et la réduction d'occlusion d'endoprothèse.
Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language:
English (
EN
)
Filing Language:
English (
EN
)